State of Wyoming Buys 19,229 Shares of Elanco Animal Health Incorporated $ELAN

Key Points

• The State of Wyoming increased its stake in Elanco Animal Health Incorporated by 126.2%, now holding 34,465 shares valued at $362,000.
• Elanco reported a net margin of 9.68% and earnings of $0.26 per share, surpassing the expectation of $0.20 in a recent quarterly report.
• 97.48% of Elanco's stock is owned by institutional investors, with several hedge funds significantly increasing their holdings in the first quarter.

State of Wyoming increased its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 126.2% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 34,465 shares of the company's stock after acquiring an additional 19,229 shares during the period. State of Wyoming's holdings in Elanco Animal Health were worth $362,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. HighTower Advisors LLC lifted its stake in Elanco Animal Health by 7.0% in the first quarter. HighTower Advisors LLC now owns 12,445 shares of the company's stock worth $131,000 after purchasing an additional 810 shares during the last quarter. Graypoint LLC raised its stake in Elanco Animal Health by 4.9% in the first quarter. Graypoint LLC now owns 26,845 shares of the company's stock worth $282,000 after buying an additional 1,256 shares in the last quarter. Commerce Bank raised its stake in Elanco Animal Health by 3.7% in the first quarter. Commerce Bank now owns 35,321 shares of the company's stock worth $371,000 after buying an additional 1,256 shares in the last quarter. Probity Advisors Inc. grew its holdings in Elanco Animal Health by 10.0% in the first quarter. Probity Advisors Inc. now owns 14,520 shares of the company's stock worth $152,000 after purchasing an additional 1,314 shares during the period. Finally, Resonant Capital Advisors LLC grew its holdings in Elanco Animal Health by 5.7% in the first quarter. Resonant Capital Advisors LLC now owns 29,414 shares of the company's stock worth $309,000 after purchasing an additional 1,576 shares during the period. 97.48% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ELAN has been the topic of a number of recent analyst reports. Piper Sandler increased their price target on shares of Elanco Animal Health from $12.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, August 11th. William Blair upgraded shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. UBS Group increased their price objective on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company a "buy" rating in a research report on Friday, August 8th. Stifel Nicolaus increased their price target on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock a "buy" rating in a research report on Wednesday, July 2nd. Finally, Leerink Partnrs upgraded shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $17.33.

Elanco Animal Health Trading Down 2.9%

Shares of Elanco Animal Health stock traded down $0.51 during trading on Wednesday, hitting $17.34. The stock had a trading volume of 6,426,123 shares, compared to its average volume of 10,757,684. The firm's fifty day simple moving average is $15.81 and its 200-day simple moving average is $12.83. The stock has a market cap of $8.61 billion, a PE ratio of 20.16, a PEG ratio of 3.41 and a beta of 1.62. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $18.87.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.06. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The business's revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the business earned $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, sell-side analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.